Form 4: Alkermes Director Brian P. McKeon Reports Acquisition of Stock Options and Restricted Stock Units

Alkermes plc Director Brian P. McKeon reported the acquisition of 13,474 non-qualified stock options and 6,142 restricted stock units on May 21, 2025, as part of his beneficial ownership.

Summary

• Brian P. McKeon, a Director of Alkermes plc (ALKS), acquired new equity awards on May 21, 2025.
• He acquired 13,474 non-qualified stock options with an exercise price of $30.53 per share.
• He also acquired 6,142 Restricted Stock Unit (RSU) awards.
• Both the stock options and RSUs are scheduled to vest in full on May 21, 2026.
• The non-qualified stock options have an expiration date of May 21, 2035.

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation for a director, which is a positive for aligning interests but does not indicate significant new operational or financial news. It's a neutral-to-slightly positive event as it shows continued commitment and compensation for a key individual.

Positives

• Director Brian P. McKeon received new equity awards (stock options and RSUs), which aligns his interests with those of the shareholders.
• The acquisition of these awards indicates ongoing compensation and retention of a key director.

Future Outlook

The vesting schedule for the acquired stock options and restricted stock units indicates that these awards will become exercisable or convertible into ordinary shares on May 21, 2026, aligning the director's future compensation with company performance.

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation. In the pharmaceutical and biotechnology industry, equity awards like stock options and RSUs are common components of executive and director compensation packages, designed to incentivize long-term performance and align interests with shareholders. This specific filing does not provide broader industry trends but reflects standard corporate governance practices.

Comparison to Industry Standards

• This filing reports standard equity compensation for a director, which is a common practice across publicly traded companies, including those in the pharmaceutical sector.
• While specific compensation amounts vary by company size, performance, and individual roles, the use of stock options and restricted stock units is a widely accepted method for executive and director remuneration.
• Without specific compensation benchmarks for comparable companies like Biogen, Gilead Sciences, or Vertex Pharmaceuticals, a direct quantitative comparison of the award size is not feasible from this document alone. However, the structure of the awards (vesting, exercise price) is consistent with typical industry practices.

Related Party Transactions

• The reported transactions involve the issuance of equity awards (stock options and restricted stock units) to a director, which are common related-party transactions in the context of executive and director compensation.

Stakeholder Impact

• Shareholders: The issuance of equity awards to a director aligns management's interests with shareholders, potentially encouraging long-term value creation. However, it also represents potential future dilution if new shares are issued upon exercise/vesting.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this specific director transaction.

Next Steps

• The acquired stock options and restricted stock units will vest on May 21, 2026.
• The stock options will expire on May 21, 2035.

Key Dates

Keywords

Alkermes plc, ALKS, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Awards, Director Compensation, Beneficial Ownership